Condition: Autoimmune Bullous Disease · Sponsor: Shandong First Medical University
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
This description comes directly from the study's public registry record.
Furen Zhang · 15854179852 · splcsy@126.com
Always discuss trial participation with your own doctor first.
| Dermatology Hospital Affiliated to Shandong First Medical University | Jinan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06900010